Antimicrobial Resistance (AMR) Economics of Innovation Taking STRIDES: The Value of Diagnostics Against AMR Read more
Chronic Diseases Value, Affordability, and… Understanding the Full Value of Long-Acting Therapies: less is more? Read more
Health Technology Assessment… Value, Affordability, and… An Analysis of NICE’s Optimised Decisions from 2015 to 2024 Read more
Health Technology Assessment… Value, Affordability, and… Broader value and societal… The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region Read more
Cell and Gene Therapies Value, Affordability, and… Budget Impact Analysis Challenges and Solutions for Budget Impact Analysis of Gene Therapies Read more
Drug Development/R&D Economics of Innovation Competition The Importance of Diversity of Supply in Rare Diseases Markets Read more © VK Studio at stock.adobe.com
Back News 11 min read 1st January 2013 Best Wishes for the New Year! Share: Twitter LinkedIn Facebook has-icon Email Copy URL Related News News June 2025 OHE statement on 2025 Spending Review Read more News May 2025 OHE responds to the Trump administration’s Executive Order on Drug Prices Read more News March 2025 OHE to host the Health Economists’ Study Group Summer 2025 Read more News December 2024 OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’ Read more
News December 2024 OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’ Read more